Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Pfizer

Status and phase: Completed; Phase 2

Conditions: Thyroid Neoplasms

Treatments: Drug: AG-013736

Study type: Interventional

Funder types: Industry

Identifiers

NCT00389441

A4061027

Details and patient eligibility

About

The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine

Full description

Additional study details: assess safety and efficacy

Enrollment: 52 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer
• At least 1 measurable target lesion, as defined by RECIST

Exclusion criteria

• Thyroid lymphoma
• Previous treatment with anti-angiogenesis agents
• No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism within 12 months prior.

Trial design

52 participants in 1 patient group

A

Experimental group

Treatment:

Drug: AG-013736